AbbVie Inc (NYSE:ABBV), Celgene Corporation (NASDAQ:CELG), and Sanofi SA (ADR) (NYSE:SNY) got the approval of the medical advisory committee of the European Union last Friday, allowing the drug makers to sell key brands, at least two of which are estimated to be market blockbusters. AbbVie Inc (NYSE:ABBV) was given a positive review on its Viekirax…
Allergan, Inc. (AGN)’s Board Of Directors Give Consent For Actavis PLC (ACT) Merger
Both Allergan, Inc. (NYSE:AGN) and Actavis plc (NYSE:ACT) have come together to form one of the biggest pharmaceutical companies of the world with projected pro forma revenue of $23 billion in 2015. Under the current offer, Allergan would receive $66 billion in cash and shares of Actavis. The combined company would be able to market…
Allergan, Inc. (NYSE:AGN) Close to $65 Billion Buyout by Actavis Plc (NYSE:ACT)
Botox maker Allergan, Inc. (NYSE:AGN) is close to completing a deal with Actavis Plc (NYSE:ACT) in a buy-out transaction amounting to about $65.5 billion. A report by Reuters, citing unnamed sources, indicates that Actavis puts Allergan shares at the range of $215 – $220, and the final price is likely to be on the higher…
Wal-Mart Stores, Inc. (WMT) Started Low-Cost Primary Healthcare Services Which Is A Big Challenge For CVS Health Corp (CVS) and Walgreen Company (WAG)
Wal-Mart Stores, Inc. (NYSE:WMT), the leading retail store chain of the U.S., is all set to revolutionize the healthcare industry, as it did eight years ago by dropping generic prescription drug prices to $4. The retailer opened its first Walmart Care Clinic in Dalton, Ga., which would cost only $40 for a regular doctor visit.…
Ibio Inc (IBIO) and Sarepta Therapeutics Inc (SRPT) Are Playing Their Ebola Cards To Attract Investors
There is a new market for drug makers as Ebola becomes a real threat in West Africa and is sturdily spreading to other areas. Several pharmaceutical companies and research institutions have been working around the clock to get a reliable treatment for the virus. Sarepta Therapeutics Inc (NASDAQ:SRPT) is one such company. On Thursday, the…
AbbVie Inc (ABBV) Reevaluates Acquisition of Shire PLC (ADR) (SHPG) Over New U.S. Tax Rules
AbbVie Inc (NYSE:ABBV) is said to be considering withdrawing its bid for the acquisition of its UK based competitor Shire PLC (ADR) (NASDAQ:SHPG), citing new tax rules by the U.S. government. The U.S. drug firm had agreed to acquire the UK rival in a $52 billion deal. The U.S. Company said that it will have…
Alpha Pro Tech, Ltd. (APT) And Lakeland Industries, Inc. (LAKE) Saw Big Declines Although Protective Gear Is Likely to Reach Higher Demand
After the World Health Organization announced a slowdown in Ebola spreading, the shares of leading Ebola associated stocks including Alpha Pro Tech, Ltd. (NYSEMKT:APT) And Lakeland Industries, Inc. (NASDAQ:LAKE) plunged in the day’s trading. At the same time, demand for protective gear is likely to reach higher in near future. The shares of Alpha Pro…
Lakeland Industries, Inc. (LAKE), Alpha Pro Tech, Ltd. (APT), Ibio Inc (IBIO) Lead Biotech Stock Industry Amid Rising Ebola Fears in US
After having several governments under its worry-trap, Ebola has started influencing the stock market and Lakeland Industries, Inc. (NASDAQ:LAKE), Alpha Pro Tech, Ltd. (NYSEMKT:APT), Ibio Inc (NYSEMKT:IBIO) are among the primary gainers of the crisis. In the last few weeks, most of the biotech companies and biopharmaceuticals associated with Ebola products have witnessed a sharp…
Lakeland Industries, Inc. (LAKE) And Alpha Pro Tech, Ltd. (APT) Have Huge Potential With Their Protective Solutions For Ebola
The continued fears of Ebola have boosted the shares of companies indulged in protective clothing manufacturing. The shares of Lakeland Industries, Inc. (NASDAQ:LAKE) and Alpha Pro Tech, Ltd. (NYSEMKT:APT) witnessed an upward trend after the likeliness of heightened demand of protective wear. The shares of Lakeland Industries, Inc. (NASDAQ:LAKE) rose up to 10.78% on Friday…
Gilead Sciences, Inc. (GILD) Wins FDA Approval for Hepatitis C Drug That Costs More Than $1000 a Pill
Gilead Sciences, Inc. (NASDAQ:GILD) has finally secured U.S. Food and Drug Administration’s approval for its Hepatitis C drug. The once-a-day pill is however coming into the market even pricier than Solvadi, which costs $1000 a pill. The drug, which is the first only oral full treatment for the illness is said to cost $1125. The…